
BioNano Genomics BNGO
$ 1.16
2.65%
Annual report 2025
added 03-23-2026
BioNano Genomics Cost of Revenue 2011-2026 | BNGO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue BioNano Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.3 M | 30.4 M | 26.6 M | 21.9 M | 14.1 M | 5.73 M | 6.77 M | 8.71 M | 6.03 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.4 M | 5.73 M | 15.1 M |
Quarterly Cost of Revenue BioNano Genomics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 M | 3.26 M | 3.52 M | - | 14.5 M | 5.19 M | 5.94 M | - | 6.57 M | 6.35 M | 5.34 M | - | 5.41 M | 5.2 M | 4.84 M | - | 3.5 M | 2.42 M | 2.12 M | - | 1.46 M | 603 K | 856 K | 1.69 M | 2.38 M | 1.56 M | 1.15 M | 2.99 M | 3.07 M | 1.81 M | 841 K | 1.5 M | 1.69 M | 1.64 M | 1.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.5 M | 603 K | 3.42 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
2.91 B | $ 117.31 | 1.94 % | $ 35.7 B | ||
|
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | ||
|
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
45.5 M | $ 16.76 | 4.39 % | $ 893 M | ||
|
Interpace Biosciences
IDXG
|
14.6 M | $ 2.2 | -4.35 % | $ 9.73 M | ||
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
222 K | $ 1.44 | 5.11 % | $ 1.92 M | ||
|
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | ||
|
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
60.2 M | $ 23.52 | 1.69 % | $ 653 M | ||
|
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | ||
|
Myriad Genetics
MYGN
|
248 M | $ 4.6 | 5.63 % | $ 426 M | ||
|
Danaher Corporation
DHR
|
10 B | $ 195.23 | 2.99 % | $ 139 B | ||
|
NeoGenomics
NEO
|
413 M | $ 7.96 | 3.51 % | $ 1.02 B | ||
|
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
1.51 B | $ 126.4 | 4.52 % | $ 20.1 B | ||
|
Fulgent Genetics
FLGT
|
176 M | $ 15.33 | 6.2 % | $ 464 M | ||
|
Guardant Health
GH
|
349 M | $ 81.93 | 4.24 % | $ 10.3 B | ||
|
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | ||
|
Senseonics Holdings
SENS
|
19.5 M | $ 6.69 | 0.15 % | $ 279 M | ||
|
Biomerica
BMRA
|
4.81 M | $ 2.09 | -1.88 % | $ 4.8 M | ||
|
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | ||
|
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 28.55 | 0.87 % | $ 20 B | ||
|
ICON Public Limited Company
ICLR
|
3.97 B | $ 109.57 | 2.58 % | $ 9.04 B | ||
|
Soleno Therapeutics
SLNO
|
2.7 M | $ 52.66 | 0.05 % | $ 2.68 B | ||
|
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 264.34 | 1.31 % | $ 22 B | ||
|
Natera
NTRA
|
158 M | $ 200.92 | 4.08 % | $ 19.8 B | ||
|
Lantheus Holdings
LNTH
|
600 M | $ 81.32 | 0.91 % | $ 5.49 B | ||
|
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | ||
|
Neuronetics
STIM
|
76.8 M | $ 1.39 | 2.59 % | $ 91.7 M | ||
|
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 191.77 | 0.13 % | $ 21.3 B | ||
|
Neogen Corporation
NEOG
|
473 M | $ 9.34 | -0.9 % | $ 2.03 B | ||
|
ENDRA Life Sciences
NDRA
|
173 K | $ 5.19 | 5.06 % | $ 4.08 M | ||
|
Organovo Holdings
ONVO
|
5 K | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
3.32 M | - | -16.95 % | $ 1.54 M |